Navigation Links
Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making three poster presentations at the 46th Annual Meeting of the European Society of Pediatric Endocrinology in Helsinki, Finland June 27 -- 30, 2007 (www.espe2007.org).


The three abstracts feature Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, including a study in juveniles. The Company previously announced that it is preparing for a Phase 3 clinical trial of Generex Oral-lyn in centres in the United States, Europe, and Canada. The abstracts are:

6-Month Study on the Safety and Efficacy of Oral Insulin (Generex Oral-lyn(tm)) Administered at Lunchtime in Juvenile Type-1 DM Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs;

Comparison Of Metabolic Control Of Pre-Prandial S.C. Regular Insulin Versus Prandia Oral Insulin (Generex Oral-lyn(tm)) In Adult Type-1 DM Subjects Maintained on Basal S.C. BID Isophane Insulin (NPH), by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador; and

Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy and a 13-Point Method Designed to Enhance Compliance, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein,
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
Post Your Comments:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)... -- A novel wearable injector slightly larger than an Oreo ... patients to self-inject prescription drugs in the large doses ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   ... of injector that does not exist today for self-administration ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 20 Thomson Reuters, a global provider ... the newest version of its award-winning Clinical ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: ... hospital-based clinicians to access complete patient clinical ...
... VPHM ) third quarter financial results for 2010 ... before the open of the U.S. financial markets. ... webcast at 9:00 a.m. Eastern Time on the same day. ... third quarter financial results and other business. ...
Cached Medicine Technology:Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Feb. 8 Aton Pharma, Inc., a diversified ... has joined the company as Vice President, Commercial Operations ... A. Fishbein assumes the same role for the Ophthalmic ... LLC, Aton is focused on the development and commercialization of ...
... , , , , , ... , Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink ... of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that ... the fiscal year ended, October 31, 2009 on time. ...
... ... Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and marketer of "Clean ... Laboratory and Research Division “TerraSolv SA” has received final approval ... additional $1.3 Million laboratory service contract with the Nigerian National ...
... in the gut, triggering bone formation , MONDAY, Feb. 8 ... the gut cured osteoporosis in lab mice and rats, a ... serotonin in the gut hinders bone formation. Most current drugs ... build bone. , "New therapies that inhibit the production of ...
... divide abnormally, researchers say , MONDAY, Feb. 8 (HealthDay News) ... week may have double the risk of developing deadly pancreatic ... But the overall number of people developing the malignancy remains ... new cases last year. , "Soft drinks are linked with ...
... , WOONSOCKET, ... CVS ) today announced record revenues, operating profit, and ... ended December 31, 2009 . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... of 2009, increased $1.7 billion to $25.8 billion , up ...
Cached Medicine News:Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3Health News:Drug Cures Osteoporosis in Mice 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 3Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 3Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 5Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 6Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 7Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 8Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 9Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 10Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 11Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 12Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 13Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 14Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 15Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 16Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 17Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 18Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 19Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 20Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 21Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 22Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 23Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 24Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 25Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 26
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: